On the other hand, the co-treatment of DU145 cancer cells with TRAIL at the concentration of 100 ng/mL and paclitaxel at the concentrations of 0.25 μM and 0.5 μM decreased the percentage of CSCs to 9.1% ± 0.6% and 9.0% ± 1.0%, respectively. The gene discussed is TNFSF10; the disease is cancer.